

From: [Santo, Corbin \[JJCUS\]](#)
To: [HRSA Paperwork](#)
Cc: [Britton, Chantelle \(HRSA\)](#)
Subject: [EXTERNAL] ICR: Enrollment and Recertification of Entities in the 340B Program, OMB No. 0915-0327—Revision
Date: Monday, October 6, 2025 8:50:47 PM
Attachments: [Outlook-kex14avm.png](#)
[JJ Comments on HRSA 340B ICR 10.06.2025 FINAL.pdf](#)

Johnson & Johnson Health Care Systems Inc. (“J&J”) submits the attached comments and recommendations in response to the proposed information collection request titled, “Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program,” OMB No. 0915-0327-Revision, 90 Fed. Reg. 38167 (Aug. 7, 2025).

J&J appreciates HRSA’s attention to these comments and recommendations and welcomes further discussion as appropriate. Please do not hesitate to contact us with any questions or if additional information would be helpful.

Sincerely,
Corbin Santo

Corbin Santo

Senior Counsel, Strategic Customer Group and Policy
J&J Innovative Medicine
Global Legal Organization

csanto@its.jnj.com
T: +1 202 589 1065
M: +1 317 213 2392
jnj.com

Johnson&Johnson

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe.